Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.60 |
| ▸ | EGLN2 | Q96KS0 | 18/20 | 0.60 |
| ▸ | EGLN3 | Q9H6Z9 | 18/20 | 0.60 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13017086 | 0.88 | EGLN1 (0.76) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL13017097 | 0.86 | EGLN1 (0.66) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17633128 | 0.85 | EGLN1 (0.68) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17633387 | 0.85 | EGLN1 (0.82) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL13707449 | 0.84 | EGLN1 (0.59) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL3773677 | 0.84 | EGLN1 (0.79) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17633265 | 0.84 | EGLN1 (0.64) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17633396 | 0.84 | EGLN1 (0.62) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17633107 | 0.83 | EGLN1 (0.63) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17633119 | 0.83 | EGLN1 (0.55) | EGLN1EGLN2EGLN3CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471024-B2 | Tetrahydrofuropyridones | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471024-B2 | Tetrahydrofuropyridones | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100331358-A1 | TETRAHYDROFUROPYRIDONES | MERCK SHARP & DOHME LLC | 2010-12-30 | — | — | US | disclosed |
| US-20100331358-A1 | TETRAHYDROFUROPYRIDONES | MERCK SHARP & DOHME LLC | 2010-12-30 | — | — | US | disclosed |
| WO-2009108496-A1 | TETRAHYDROFUROPYRIDONES | MERCK & CO., INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331358-A1 | TETRAHYDROFUROPYRIDONES | HIF1AN, EGLN3, HIF1A | EGLN1 10/4885EGLN2 4/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.